We’ve now entered the 46th straight quarter of biotech IPO activity. New equity issuance for biotech in 2021 has broken records for the amount of capital raised, topping even the strong years of 2020 and 2014. Although the open and

We just held our first-ever, and hopefully only, virtual Atlas Venture Annual Meeting for our investors. Although science is winning in this pandemic, we’re clearly not back to normal yet so felt it prudent to shift to a virtual format.

By Deanna Petersen and Holly May, Chief Business Officer and Chief Commercial Officer, respectively, of AVROBIO, as part of the From The Trenches feature of LifeSciVC Moving from traditional drug development and commercialization to gene therapy development and commercialization can

By Ankit Mahadevia, CEO and founder of Spero Therapeutics, as part of the From The Trenches feature of LifeSciVC Recently, Spero announced the filing of its first ever New Drug Application, for our medicine tebipenem Hbr.  Interestingly, as we approached

By Josh Brumm, CEO of Dyne Therapeutics, as part of the From The Trenches feature of LifeSciVC One morning in early June I was reading my LinkedIn feed and saw something that caught my eye – a university was establishing

By Aoife Brennan, CEO of Synlogic Therapeutics, as part of the From The Trenches feature of LifeSciVC The COVID-19 pandemic has upended life as we know it. Given so much uncertainty, it is a normal human impulse to want some

By Philip Astley-Sparke, CEO of Replimune, as part of the From The Trenches feature of LifeSciVC. I recently stepped down after a six-year stint as Chairman of uniQure (NASDAQ: QURE). In the process of interviewing potential successors, one candidate observed

By Deanna Petersen, CBO of AVROBIO, as part of the From The Trenches feature of LifeSciVC It’s tempting to think that the first skill you need to learn in business development is negotiating. That’s important, of course, but it should

By Ankit Mahadevia, CEO and Founder of Spero Therapeutics, as part of the From The Trenches feature of LifeSciVC. The opportunity for each member of a NewCo to take on multiple responsibilities selects early for people ready to help a

By Tim Reilly & Jonathan Montagu, CDO and CEO of HotSpot Therapeutics, as part of the From The Trenches feature of LifeSciVC Now 10 years into the golden era of immuno-oncology (I-O) following the first FDA approval of ipilimumab (anti-CTLA4)

By Sam Truex, Venture Partner at Atlas Venture, as part of the From The Trenches feature of LifeSciVC. Holy cow, have we seen the rain lately – both downpours outside and a downpour of SPAC activity. In October 2020, Bruce

By Joshua Brumm, CEO of Dyne Therapeutics, as part of the From The Trenches feature of LifeSciVC When I play board games, I play to win. That requires thinking several moves ahead. In the game Risk, for instance, it’s not